ArticleFrontiers in oncology2026
The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: SEC23A, a gene implicated in vesicle transport, has an undefined role in the progression of gastric cancer (GC). This study aims to comprehensively characterize the clinical significance, molecular mechanisms, and therapeutic potential of SEC23A in GC. Methods: We systematically analyzed SEC23A expression and its prognostic value in GC cohorts from The Cancer Genome Atlas and Gene Expression Profiling Interactive Analysis. Genetic alterations were assessed using cBioPortal. Functional networks, including competitive endogenous RNA and protein-protein interaction networks, were constructed. The tumor immune microenvironment was evaluated using the Tumor Immune Estimation Resource 2.0, CIBERSORT, and single-sample gene set enrichment analysis. Drug sensitivity was predicted using data from The Cancer Immunome Atlas and the R package "pRRophetic". Key findings were validated with data from the Gene Expression Omnibus and the Human Protein Atlas. Results: Overexpression of SEC23A was significantly associated with poor overall survival in GC patients, particularly in those with undifferentiated tumors. Functionally, high SEC23A levels promoted tumor cell proliferation and were correlated with an immunosuppressive microenvironment, characterized by increased M2 macrophage infiltration and reduced Tregs. Patients with high SEC23A expression exhibited reduced sensitivity to anti-PD-1/CTLA-4 immunotherapy but showed heightened sensitivity to certain small-molecule inhibitors. Consistent with these observations, Conclusions: Our findings underscore the critical role of SEC23A in driving GC progression and modulating the immune landscape. SEC23A represents a promising prognostic biomarker and a novel therapeutic target for GC, potentially guiding strategies involving immunotherapy and small-molecule inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.